Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Shune, Leyla  [Clear All Filters]
2018
Prohaska L, Mahmoudjafari Z, Shune L, Singh A, Lin T, Abhyankar S, Ganguly S, Grauer D, McGuirk J, Clough L. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant. Hematol Oncol Stem Cell Ther. 2018.
2020
Britt A, Mohyuddin GRehman, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, et al. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res. 2020;95:106402.
Soder RP, Dawn B, Weiss ML, Dunavin N, Weir S, Mitchell J, Li M, Shune L, Singh AK, Ganguly S, et al. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. Stem Cell Rev Rep. 2020.
2021
Mushtaq MUmair, Shahzad M, Chaudhary SGull, Luder M, Ahmed N, Abdelhakim H, Bansal R, Balusu R, DeJarnette S, Divine C, et al. Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients. Transplant Cell Ther. 2021.
2023
Hashmi H, Shebli A, Jain J, Khasawneh G, Mohan M, Mahmoudjafari Z, Cui W, McGuirk J, Shune L, Ahmed N, et al. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma. Transplant Cell Ther. 2023.
Nooka AK, Kaufman JL, Rodríguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, et al. A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2023.
2024
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldes A, Stölzel F, Rathje K, Fischer L, et al. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2024:JCO2302232.
Mushtaq MUmair, Shahzad M, Amin MK, Lutfi F, DeJarnette S, Al-Ramahi JS, Li K, Ahmed N, Bansal R, Abdelhakim H, et al. Outcomes with HLA-matched unrelated donor versus haploidentical hematopoietic cell transplantation. Leuk Lymphoma. 2024:1-10.
McGuirk M, Shahzad M, Amin MKashif, Khan MAtif, Bellman P, Mudaranthakam DPal, DeJarnette S, Lutfi F, Ahmed N, Bansal R, et al. Predictors of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: Insights from a real-world experience. Transpl Immunol. 2024:102039.
Shahzad M, Khalid MFareed, Amin MKashif, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SGull, Ahmed N, et al. Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review. Hematol Oncol Stem Cell Ther. 2024;17(2):88-94.